The non-exclusive license covers the use of mesenchymal stem cells obtained from the patient’s bone marrow to develop regenerative therapy for spinal cord injuries and brain infarction. Experiments for stroke patients (phase III) are already done at Sapporo Medical University.

Nipro press release, April 28, 2014